Condition: Lung Cancer · Metastases to Lung · Radiotherapy Side Effect · Sponsor: Rigshospitalet, Denmark
An open-label phase II study, investigating toxicity, treatment efficacy and the local tumor control rate in 69 patients with centrally located tumors and in 69 patients with ultra-centrally located tumors in the lung. Treatment and patient outcomes will be recorded. Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation. Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
This description comes directly from the study's public registry record.
Mette Pøhl, MD, PhD · +4535451824 · mette.poehl@regionh.dk
Lone Hoffmann, Ass. Prof, MSc, PhD · +4529939779 · lone.hoffmann@aarhus.rm.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Not Yet Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Herlev University Hospital | Herlev, Denmark | Recruiting |
| Odense University Hospital | Odense, Denmark | Recruiting |
| Department of Oncology, Lillebaelt Hospital | Vejle, Denmark | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.